CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
克服靶向血液系统恶性肿瘤的五大挑战
英文原题：Overcoming five main challenges to targeting hematologic malignancies.
查看英文原题
Overcoming five main challenges to targeting hematologic malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法的开发和应用改变了血液系统恶性肿瘤的治疗格局。目前，FDA已批准其用于复发/难治性B细胞和浆细胞恶性肿瘤，但研究仍致力于靶向难治抗原和疾病。本综述讨论血液系统恶性肿瘤CAR-T 细胞产品面临的五项主要挑战，并提出克服这些挑战的机制和策略，包括监测不良反应、改善普遍可及性、增强生产平台及推进商业化，最终目标是实现最佳患者照护。
展开英文摘要原文
The development and application of chimeric antigen receptor (CAR) T-cell therapies have changed the treatment landscape of hematologic malignancies. While there are currently FDA approved products for their use in relapsed or refractory B-cell and plasma cell malignancies, ongoing research efforts strive to target difficult to treat antigens and diseases. In this review, we discuss five main challenges involving CAR-T cell products in hematologic malignancies.
Additionally, we propose mechanisms to overcome these challenges that monitor adverse effects, improve universal access, enhance manufacturing platforms, and advance commercialization with the goal of optimal patient care.
论文信息
- 作者
- Thakkar M、Hanley PJ、Bersenev A、Steffin DH
- 第一作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, and Texas Children's Hospital, Houston, Texas, USA.United States
- 通讯作者单位
- Center for Cell and Gene Therapy, Baylor College of Medicine, and Texas Children's Hospital, Houston, Texas, USA. Electronic address: dhsteffi@texaschildrens.org.United States
- 文献类型
- 综述
- 期刊
- Cytotherapy2026 Aug
- 原文标识
- PubMed 42247978 · DOI 10.1016/j.jcyt.2026.102776